Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237286 · ClinicalTrials.gov registry record · Phase 1
Intravenous Ketamine Plus Neurocognitive Training for Depression
A Phase 1 study of Depression, sponsored by Rebecca Price.
- Completed
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
- 1
- Study location
NCT03237286 is a Phase 1 study of Depression that has completed, run by Rebecca Price. The registered enrollment target is 154 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03237286, a Phase 1 study of Depression, has completed, sponsored by Rebecca Price.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
- 1
- Study location
Study Summary
This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training. Three of the primary outcomes listed (fMRI functional connectivity; Implicit Association Test; cognitive flexibility testing) pertain to Aim 1. For Aim 2, one primary clinical outcome (MADRS, a clinician-administered measure of depression severity) pertains to the acute (30-day) phase, while the QIDS (a self-report measure of depression severity) becomes the primary clinical outcome during the 12-month naturalistic follow-up.
Conditions Studied
Interventions
- DRUG Intravenous ketamine
- BEHAVIORAL Computer-based Cognitive Training
Study Locations (1)
Pennsylvania
- Western Psychiatric Institute and Clinic - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2022-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03237286
The ClinicalTrials.gov registry entry for NCT03237286 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (80% lower). The listed sponsor is Rebecca Price, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Intravenous ketamine is the first listed.
NCT03237286 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03237286 about?
NCT03237286 is a clinical study titled "Intravenous Ketamine Plus Neurocognitive Training for Depression". This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training. Three of the primary outcomes listed (fMR...
What is the current status of trial NCT03237286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2017-12-01. Estimated completion is 2022-10-18.
What conditions does trial NCT03237286 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT03237286?
The interventions under investigation include: Intravenous ketamine (DRUG), Computer-based Cognitive Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT03237286?
This trial is sponsored by Rebecca Price, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03237286 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
RECRUITING · Phase 1
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
RECRUITING · Phase 1
-
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.